Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
3T Biosciences Inc. is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The data shows that these matters are distributed among 4 distinct examiners, meaning no two pending actions are being handled by the same person. This distribution indicates that the company's patent applications are receiving a wide range of scrutiny from different officials. Additionally, the prosecution is occurring across 4 distinct art units, which reflects the diverse technical nature of the company's biological or pharmaceutical innovations.
The busiest examiner for this portfolio is RAYMONDA, MATTHEW HAROLD, who is assigned 1 busiest examiner pending office action. Because the total number of pending office actions is 4, the busiest examiner only manages a portion of the company's current workload. This lack of concentration requires the company to manage four separate examiner relationships simultaneously. Practitioners should be prepared for varying examination styles, as the 4 distinct art units likely have different internal cultures and standards. The outcome of the 4 pending office actions will provide a broad view of how the company's technology is perceived across several different divisions of the patent office.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAYMONDA, MATTHEW HAROLD | 1 | 40.0% | +47.7% |
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 49d overdue |
| 18157618 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800993 | YEAST DISPLAY LIBRARIES, ASSOCIATED COMPOSITIONS, AND ASSOCIATE METHODS OF USE | ESPINOSA, CLAUDIA EDILMA | 89d overdue |
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 49d overdue |
| 18685109 | PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use | RAYMONDA, MATTHEW HAROLD | — |
| 18157618 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| 1674 | 1 |
| 1633 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685109 | PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use | RAYMONDA, MATTHEW HAROLD | 1684 | §102§103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18157618 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | PAK, MICHAEL D | 1674 | §103§112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§103§112 | Final Rejection | 49d overdue | Pending | Jan 20, 2023 |
| 17800993 | YEAST DISPLAY LIBRARIES, ASSOCIATED COMPOSITIONS, AND ASSOCIATE METHODS OF USE | ESPINOSA, CLAUDIA EDILMA | 1654 | §103DP | Final Rejection | 89d overdue | Pending | Aug 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial3T Biosciences Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Matthew Harold Raymonda has the most, with 1 of 3T Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
